Mounjaro for Prediabetes: Evidence, Eligibility, Coverage
Mounjaro is not FDA approved for prediabetes. It is approved for type 2 diabetes and heart risk. Some doctors prescribe it when one of those uses also applies. In SURMOUNT-1, people on Zepbound lost 20.9% of body weight on average, vs 3.1% on placebo.
- Active ingredient
- tirzepatide
- How it is taken
- weekly injection
- Approved for
- Type 2 diabetes and heart risk
- Best result (SURMOUNT-1)
- 20.9% weight loss
Mounjaro: the basics
Its half-life is about 5 days. After 5 d, half is gone, and about 3% remains after five half-lives, or 25 days.
In SURPASS-1, people with type 2 diabetes lost 7.8 kg over 40 weeks, compared with 1 kg on placebo.
Shown in US dollars, each month's figures give the list price plus the self-pay offers, all taken from the price page the maker posts.
Sources: FDA label (DailyMed), healthsystemtracker.org, pricinginfo.lilly.com.
Who qualifies?
| Who sets the rule | Who qualifies |
|---|---|
| FDA label | Lower blood sugar is seen in Children 10 and older and in adults who have type 2 diabetes when the drug is taken with diet and exercise. |
| FDA label | For adults with type 2 diabetes at high risk, taking this drug reduces the risk of heart attack, stroke, or heart-related death. |
| Typical commercial plan (Aetna policy) | BMI 30 or higher |
| Typical commercial plan (Aetna policy) | BMI 27 or higher with a weight-related condition |
| Typical commercial plan (Aetna policy) | first, finish a diet and activity program of 6 months |
Sources: FDA label on DailyMed, aetna.com.
Trial results for prediabetes
Not one of these studies limited enrollment to prediabetes alone. Participants were adults with obesity or overweight who did not have diabetes, plus adults with obesity who did not have type 2 diabetes.
| Trial | Medicine | Who took part | Length | People | Main result | Comparison |
|---|---|---|---|---|---|---|
| SURMOUNT-1 |  Zepbound | Adults with obesity or overweight, without diabetes | 72 weeks | 2,539 | 20.9% weight loss | 3.1% on placebo |
| SURMOUNT-5 | Zepbound | Adults with obesity, without type 2 diabetes | 72 weeks | 751 | 20.2% weight loss | Not listed |
Sources of the trials: SURMOUNT-1 (FDA label (DailyMed)) and SURMOUNT-5 (PubMed).
What is different when you have prediabetes?
| What changes | What the label says |
|---|---|
| Hypoglycemia When You Use It With Insulin Secretagogues or Insulin | Taking it together with insulin or a sulfonylurea makes low blood sugar more likely, and those doses may need to be lowered. |
| Taken with insulin or sulfonylureas | When you take this medicine with insulin or with a sulfonylurea (glipizide or glimepiride are examples), your chance of low blood sugar goes up. The doctor may lower the dose of insulin or the sulfonylurea. |
From the FDA labels, here is the FDA label (DailyMed).
From the warnings in the label: FDA label (DailyMed).
How prediabetes coverage is handled
A GLP-1 used only for weight loss is not covered by Medicare Part D.
In places where Medicaid covers weight-loss GLP-1s, Prior authorization is standard.
Sources listed here: humana.com and KFF.
- Mounjaro Coupon and Savings Card
- Mounjaro Price
- Cheapest Way to Get Mounjaro
- Mounjaro Cost Without Insurance
- Mounjaro Cost With Insurance
- Mounjaro Insurance Coverage
- Does Medicare Cover Mounjaro? Part D Rules, the Bridge, Copays
- Does BCBS Cover Mounjaro? Diabetes-Only Rules by Plan, Appeals
- Mounjaro Patient Assistance
Alternatives for prediabetes
| Medicine | For prediabetes | How it is taken | Trial result |
|---|---|---|---|
| Mounjaro | Not a listed use | weekly injection | Not listed |
 Ozempic | Not a listed use | weekly injection | Not listed |
 Wegovy | Not a listed use | weekly injection or daily tablet | 14.9% weight loss |
 Rybelsus | Not a listed use | daily tablet | Not listed |
| Zepbound | Not a listed use | weekly injection | 20.9% weight loss |
 Foundayo | Not a listed use | daily tablet | 11.1% weight loss |
 Trulicity | Not a listed use | weekly injection | Not listed |
 Saxenda | Not a listed use | daily injection | 7.4% weight loss |
 Victoza | Not a listed use | daily injection | Not listed |
| Byetta | Not a listed use | twice-daily injection | Not listed |
Sources: FDA label (DailyMed).
What to ask your prescriber
- For coverage, does my prediabetes count as a condition related to weight?
- Would a weight-loss brand suit you better than a diabetes brand?
For the complete label text, read the full prescribing information for Mounjaro on DailyMed.